Seo Jung-jin Celltrion

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

South Korea's low-cost carrier Jin Air announced on Friday that it will resume flights on the Incheon to Hong Kong route on July 18.This marks the r...

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...

Samsung Group heiress and Hotel Shilla Chief Executive Lee Boo-jin sold 441.2 billion won ($325.9 million) worth of Samsung Electronics Co. shares i...

Shinhan Financial Group Co., South Korea's second-largest financial group, plans to build a new high-rise office tower in Seoul’s central busi...

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

South Korea's low-cost carrier Jin Air announced on Friday that it will offer various benefits to passengers on its Japan routes until Mar. 24.Jin A...

Chung Yong-jin, vice chairman of South Korea’s retail giant Shinsegae Group, has been promoted to chairman to strengthen his clout over the co...

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Sindoh Co., a leading manufacturer of multi-functional printers in South Korea, is set to tap an investment banking expert as its chief executive. W...

South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...

Samsung Electronics Co. announced on Thursday that it will release the worldwide famous pianist Seong-Jin Cho’s live performance video in 8K...

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

Sovereign wealth fund Korea Investment Corporation (KIC) said on Monday it has launched its Mumbai office, establishing the state-run fund’s f...

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...

South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the...

South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...

Celltrion Inc., South Korea's leading biosimilar maker, on Wednesday expressed its ambition to join the global top 10 biotech and pharmaceutical com...

South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...

South Korea’s Celltrion Inc. will divest of a portfolio of Takeda Pharmaceutical's prescription medicines sold in Asia to CBC Group, a Singapo...

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...

Campbell Lutyens & Co. Ltd., a UK private equity advisory firm, has tapped sovereign wealth fund Korea Investment Corporation (KIC) former PE he...

South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...

Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...

South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup ...

Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...